

## PEGEIVED CENTRAL FAX GENTER JUL 1 0 2008

Onyx Pharmaceuticals, Inc. 2100 Powell Street Emeryville, CA 94608 www.onyx-pharm.com Tel. 510.597-6500 Fax 510.597-6600

#### FACSIMILE TRANSMITTAL FORM

Date:

10 July 2008

To:

Commissioner for Patents

United States Patent and Trademark

Office

Fax:

1-571-273-8300

From:

Gregory J. Giotta

Registration No. 32,028

Phone:

(510) 597-6502

Fax:

(510) 597-6600

Re:

U.S. Patent Application Serial No. 10/669,768 (Onyx Reference No. Onyx 1047.DIV)

Number Of Pages Including Cover Sheet: 4 ( Four pages)

#### Message

# THE ATTACHED DOCUMENTS ARE TO BE MADE OF OFFICIAL RECORD

Transmitted herewith for filing in the above-referenced application are the following documents:

- 1. Transmittal;
- 2. Notification of Change from Small Entity to Large Entity Status and
- 3. Certificates of Transmission by Facsimile.

WARNING: This facsimile message and accompanying documents are intended only for the use of the addressee indicated above. Information that is privileged or otherwise confidential may be contained therein. If you are not the intended recipient, you are hereby notified that any dissemination, copying, review or use of this message, documents or information contained therein is strictly prohibited. If you have received this message in error, please notify us immediately by telephone or facsimile and mail the original to us at the above address. Thank you.

# CENTRAL FAX CENTER Onyx Dkt No. 1047.DIV

USSN: 10/669,768

JUL 1 0 2008

PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.

Ann S. Chihak Poff Signature

Date of Transmittal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No.: 8135 In Re Application of: Shen, Y.J., et al.

Art Unit: 1633 Serial No.: 10/669,768

Examiner: Marvich, Maria Filing Date: 24 Sep 2003

Title: ADENOVIRUS E1B-55K SINGLE AMINO ACID MUTANTS AND METHODS

OF USE

#### TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-referenced application are the following documents:

- 1. Transmittal;
- 2. Notification of Change from Small Entity to Large Entity Status;
- 3. Certificates of Transmission by Facsimile.

Authorization to Charge Deposit Account:

# RECEIVED CENTRAL FAX CENTER

JUL 1 0 2008

NO. 786 P. 3

Onyx Dkt No. 1047.DIV USSN: 10/669,768

**PATENT** 

No additional fees are believed due. However, the Commissioner is hereby authorized to charge to Deposit Account No. 15-0615 any fees (please reference ONYX 1047.DIV) under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated:

Rν

By:

теgory Gietta, Ph.D., Esq

Registration No. 32,028 Attorney for Applicant

ONYX Pharmaceuticals, Inc.

ONYX Pharmaceuticals, Inc.

2100 Powell Street

Emeryville, CA 94608

Phone: (510) 597-6502

Facsimile: (510) 597-6610

## HEGBIVED CENTRAL FAX CENTER

JUL 1 0 2008

Onyx Dkt No. 1047.DIV

USSN: 10/669,768 PATENT

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)	
I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, United	
States Patent and Trademark Office, (Fax No. 571-273-8300) on the date indicated.	
States I desir and Tradelinary Oxyge, (2 de 1767)	
Alle Carino 2 110	60/01/ED

Signature Ann S. Chihak Poff

Date of Transmittal

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Confirmation No.: 8135 In Re Application of: Shen, Y.J., et al. Art Unit: 1633 Serial No.: 10/669,768 Examiner: Marvich, Maria Filing Date: 24 Sep 2003 Title: ADENOVIRUS E1B-55K SINGLE AMINO ACID MUTANTS AND METHODS OF USE

#### Notification of Change from Small Entity to Large Entity Status

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant 37 C.F.R. §1.27(g)(2), the status of the above-identified application should be changed from SMALL ENTITY status to LARGE ENTITY status.

No fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. 15-0615 (please reference ONYX 1047.DIV) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

¶Qiotta, Ph.**Ŋ**., Esq.

Registration No. 32,028 Attorney for Applicant Onyx Pharmaceuticals, Inc.